PMID- 25331387
OWN - NLM
STAT- MEDLINE
DCOM- 20150908
LR  - 20181202
IS  - 1671-167X (Print)
IS  - 1671-167X (Linking)
VI  - 46
IP  - 5
DP  - 2014 Oct 18
TI  - [Evaluation and indication of human epithelial growth factor receptor 2 status in 
      breast carcinoma with amplified chromosome].
PG  - 686-90
AB  - OBJECTIVE: To study the evaluation of human epithelial growth factor receptor 2 
      (HER2) status in breast carcinoma with amplified chromosome 17 centromere locus 
      (CEP17) and clinical significance of CEP17 amplification. METHODS: Two 
      hundred-eighteen cases of breast carcinoma were collected. We performed 
      immunohistochemistry (IHC) to test HER2 protein and fluorescence in situ 
      hybridization (FISH) to evaluate HER2 gene status. RESULTS: Two cases in this 
      cohort manifested CEP17 amplification. HER2 signals for case 1 was countable, and 
      the average number was 2.6 per one nuclei, and the signals of CEP17 were 
      clustered or multipunctiform. This case was evaluated as no HER2 amplification, 
      but with amplified CEP17 . In case 2 the signals of HER2 and CEP17 were 
      countable, and the average number of HER2 signal was 6.8 per one nucleus while 
      CEP17 signal was 5.9 per one nucleus. The status was considered as HER2 and CEP17 
      coamplification. And the levels of HER2 protein expression of these two cases 
      were both two plus. CONCLUSION: The incidence of CEP17 amplification in breast 
      carcinoma is rare, with or without HER2 amplification. We recommend to evaluate 
      the exact HER2 status by the HER2 copy number, and should also analyze the 
      HER2/CEP17 ratio and the level of HER2 protein, for providing more accurate 
      evidence to support the clinical target therapy.
FAU - Zhang, Shuang
AU  - Zhang S
AD  - Department of Pathology, Peking University First Hospital, Beijing 100034, China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Department of Pathology, Peking University First Hospital, Beijing 100034, China.
FAU - Guo, Zheng-min
AU  - Guo ZM
AD  - Department of Pathology, Peking University First Hospital, Beijing 100034, China.
FAU - Zhang, Hong
AU  - Zhang H
AD  - Department of Pathology, Peking University First Hospital, Beijing 100034, China.
FAU - Xu, Ling
AU  - Xu L
AD  - Breast Center, Peking University First Hospital, Beijing 100034, China.
FAU - Liu, Yin-hua
AU  - Liu YH
AD  - Breast Center, Peking University First Hospital, Beijing 100034, China.
FAU - Li, Ting
AU  - Li T
AD  - Department of Pathology, Peking University First Hospital, Beijing 100034, China.
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Beijing Da Xue Xue Bao Yi Xue Ban
JT  - Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health 
      sciences
JID - 101125284
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/genetics/*metabolism
MH  - Centromere/genetics/metabolism
MH  - Chromosomes, Human, Pair 17
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/genetics/*metabolism
EDAT- 2014/10/22 06:00
MHDA- 2015/09/09 06:00
CRDT- 2014/10/22 06:00
PHST- 2014/10/22 06:00 [entrez]
PHST- 2014/10/22 06:00 [pubmed]
PHST- 2015/09/09 06:00 [medline]
PST - ppublish
SO  - Beijing Da Xue Xue Bao Yi Xue Ban. 2014 Oct 18;46(5):686-90.